<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A recent meta-analysis evaluated trials of the rapid-acting analogues insulin lispro and insulin aspart, performed before the introduction of the basal analogues, insulin glargine and insulin detemir </plain></SENT>
<SENT sid="1" pm="."><plain>This article reviews the effect of rapid-acting and basal insulin analogues separately and in combination, relative to human insulin </plain></SENT>
<SENT sid="2" pm="."><plain>Outcomes evaluated include HbA(1c), <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> (<z:chebi fb="73" ids="53262">PPG</z:chebi>), and weight changes </plain></SENT>
<SENT sid="3" pm="."><plain>Results from trials that matched defined criteria are presented in tables </plain></SENT>
<SENT sid="4" pm="."><plain>In type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, compared with human insulin, the rapid-acting analogues generally reduced <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi>, whereas the basal analogues tended to reduce <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> -- particularly nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0005456'>Weight gain</z:mp> may also be reduced with basal analogues, compared with human basal insulin </plain></SENT>
<SENT sid="6" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, premix rapid-acting analogues controlled postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> better than human insulin mixes; basal analogues used as basal-only therapy reduced <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin; and some advantages were apparent with analogues in basal-bolus therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Whilst the benefits on individual metabolic and clinical outcomes appear modest, almost <z:hpo ids='HP_0000001'>all</z:hpo> studies report some advantage when using insulin analogues in type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Significant benefits, including <z:chebi fb="73" ids="53262">PPG</z:chebi> lowering with the rapid-acting analogues and the potential for reduction in cardiovascular risk, should be investigated further </plain></SENT>
</text></document>